Dr. Reddy's launches Glimy MP 1 and Glimy MP2.
Triple drug combination ideal to address the triple defects in diabetes

Hyderabad, India, July 10, 2007: Glimy MPTM (Glimepiride+ Metformin+ Pioglitazone) has been launched nationwide in July 07 marking the entry of Dr. Reddy’s in the triple drug combination oral hypoglycemic agents market. Glimy MPTM is an extension of the existing products of Dr.Reddy’s used in the management of Type 2 diabetes. It is a one step approach to intensive glycemic control.

Glimy MPTM is available in dosages of 1mg (Glimy MP1) and 2mg (Glimy MP2), in sizes of 10tabs / strip and 10strips/pack. The triple drug combination offers the range of options available for the doctor to address their needs in different situations in the management of type 2 diabetes.

Notes to the editor:

• The triple drug combination oral hypoglycemic agents market is about Rs 62 crore in size and has grown by 176% in the last one year (as per ORG MAT April’07)
• Glimy MPTM is a new brand extension. Existing products of Dr.Reddy’s are GLIMY (Glimepiride 1,2,3,4 mg tabs), GLIMY-M (Glimepiride1 & 2 mg+ Metformin ER 500mg) and GLIMY-P (Glimepiride + Pioglitazone)
• Dr.Reddy’s is the first company to emphasize on HbA1C(Glycosylated Hemoglobin level) target as < 6.5%
• Glimy MPTM helps patients achieve the level of HbA1C < 6.5%
• Other brands of Dr.Reddy’s in this segment are ReclideTM & ReclimetTM
  Brief mode of action of Glimy MPTM
• Diabetes is a metabolic disease with three anomalies i.e. reduced insulin secretion, decreased insulin sensitivity & increased hepatic glucose production.
• Glimepiride works by increasing the insulin secretion (act on Pancreas), Metformin acts by decreasing the hepatic glucose output (act on Liver), and Pioglitazone acts by increasing the insulin sensitivity (act on peripheral tissues).
• Thus the triple combination addresses all the three anomalies in diabetes & thereby helps patients to achieve the target goal of HbA1C <6.5.

Disclaimer:
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's:
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer.

www.drreddys.com

Contact Information:

Investors and Financial Analysts:
Nikhil Shah at nikhilshah@drreddys.com or on +91-40-23731946 ext. 308

Media:
M Mythili at mythilim@drreddys.com or on +91-40-66511620.